CheckMate 227 Part 1 [93] showed that nivolumab and ipilimumab prolong OS compared with chemotherapy in patients with metastatic NSCLC, regardless of tumor programmed death ligand 1 (PD-L1) expression. The gene discussed is CD274; the disease is non-small cell lung carcinoma.